To purchase hard copies of this book, please email:
orders@intechopen.com
By only printing on demand InTech ensures our carbon footprint is kept to a minimum.
The data below shows the environmental impact of printing one single book:
62.91 kg wood
3.38 g CO2
57.12 ml Water
Share this page
Targets in Gene Therapy
Edited by Yongping You, ISBN 978-953-307-540-2, Hard cover, 436 pages, Publisher: InTech, Published: August 23, 2011 under CC BY-NC-SA 3.0 license, in subject Medical Genetics
DOI: 10.5772/1012
This book aims at providing an up-to-date report to cover key aspects of existing problems in the emerging field of targets in gene therapy. With the contributions in various disciplines of gene therapy, the book brings together major approaches: Target Strategy in Gene Therapy, Gene Therapy of Cancer and Gene Therapy of Other Diseases. This source enables clinicians and researchers to select and effectively utilize new translational approaches in gene therapy and analyze the developments in target strategy in gene therapy.
This book is indexed in:
Book contents
- Chapter 1Choosing Targets for Gene Therapy
- Chapter 2Gene Modulation by Peptide Nucleic Acids (PNAs) Targeting microRNAs (miRs)
- Chapter 3Effective Transgene Constructs to Enhance Gene Therapy with Trichostatin A
- Chapter 4Suicide Gene Therapy by Herpes Simplex Virus-1 Thymidine Kinase (HSV-TK)
- Chapter 5Translational Challenges for Hepatocyte-Directed Gene Transfer
- Chapter 6Physiologically-Regulated Expression Vectors for Gene Therapy
- Chapter 7PLP-Dependent Enzymes: a Potent Therapeutic Approach for Cancer and Cardiovascular Diseases
- Chapter 8Improvement of FasL Gene Therapy In Vitro by Fusing the FasL to Del1 Protein Domains
- Chapter 9Feasibility of BMP-2 Gene Therapy Using an Ultra-Fine Needle
- Chapter 10Current Strategies for Cancer Gene Therapy
- Chapter 11Gene Therapy Strategy for Tumour Hypoxia
- Chapter 12Gene Therapy of Glioblastoma: Anti – Gene Anti IGF-I Strategy
- Chapter 13Mechanism of Hypoxia-Inducible Factor-1alpha Over- Expression and Molecular-Target Therapy for Hepatocellular Carcinoma
- Chapter 14Cancer Gene Therapy via NKG2D and FAS Pathways
- Chapter 15Emergence of IFN-lambda as a Potential Antitumor Agent
- Chapter 16Intramuscular IL-12 Electrogene Therapy for Treatment of Spontaneous Canine Tumors
- Chapter 17Gene Therapy Targets and the Role of Pharmacogenomics in Heart Failure
- Chapter 18Gene Therapy of the Heart through Targeting Non-Cardiac Cells
- Chapter 19Transplantation of Sendai Viral Angiopoietin-1-Modified Mesenchymal Stem Cells for Ischemic Heart Disease
- Chapter 20Using Factor VII in Hemophilia Gene Therapy
- Chapter 21The Different Effects of TGF-β1, VEGF and PDGF on the Remodeling of Anterior Cruciate Ligament Graft
- Chapter 22Different ex Vivo and Direct in Vivo DNA Administration Strategies for Growth Hormone Gene Therapy in Dwarf Animals
- Chapter 23Protection from Lethal Cell Death in Cecal Ligation and Puncture-Induced Sepsis Mouse Model by In Vivo Delivery of FADD siRNA
- Chapter 24Muscle-Targeted Gene Therapy of Charcot Marie-Tooth Disease is Dependent on Muscle Activity
